EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A vaccine against cytomegalovirus: how close are we?

Sallie R Permar, Mark R Schleiss, Stanley A Plotkin

Journal of Clinical Investigation · 02.01.2025 · 135 (1)

DOI: 10.1172/jci182317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.01.2025. Verfasst von Sallie R Permar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Weill Cornell Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Cytomegalovirus, Cytomegalovirus Infections, Cytomegalovirus Vaccines. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pursuit of a vaccine against the human cytomegalovirus (HCMV) has been ongoing for more than 50 years. HCMV is the leading infectious cause of birth defects, including damage to the brain, and is a common cause of complications in organ transplantation. The complex biology of HCMV has made vaccine development difficult, but a recent meeting sponsored by the National Institute of Allergy and Infectious Diseases in September of 2023 brought together experts from academia, industry, and federal agencies to discuss progress in the field. The meeting reviewed the status of candidate HCMV vaccines under study and the challenges in clinical trial design in demonstrating efficacy against congenital CMV infection or the reduction of HCMV disease following solid organ transplantation or hematopoietic stem cell transplantation. Discussion in the meeting revealed that, with the numerous candidate vaccines that are under study, it is clear that a safe and effective HCMV vaccine is within reach. Meeting attendees achieved a consensus opinion that even a partially effective vaccine would have a major effect on the global health consequences of HCMV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesHumansClinical Trials as TopicHematopoietic Stem Cell TransplantationOrgan Transplantation

Substanzen

Cytomegalovirus Vaccines

Autor:innen und Institutionen

  • Department of Pediatrics, Weill Cornell Medical Center, New York, New York, USA.
  • Division of Pediatric Infectious Diseases and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Vaxconsult, Doylestown, Pennsylvania, USA.

Förderung

  • NICHD NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Permar, S. R., Schleiss, M. R., & Plotkin, S. A. (2025). A vaccine against cytomegalovirus: how close are we?. Journal of Clinical Investigation, 135(1). https://doi.org/10.1172/jci182317

Vancouver

Permar SR, Schleiss MR, Plotkin SA. A vaccine against cytomegalovirus: how close are we?. Journal of Clinical Investigation. 2025;135(1). doi:10.1172/jci182317

BibTeX
@article{Permar2025,
  author = {Permar, Sallie R and Schleiss, Mark R and Plotkin, Stanley A},
  title = {A vaccine against cytomegalovirus: how close are we?},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {1},
  doi = {10.1172/jci182317}
}
Kostenlos starten →